Bruno Montanari
Partner @ Seroba Life Sciences
Paris, France
Bruno Montanari is a Series A investor at Seroba Life Sciences in Paris focused on Health Care and Biotechnology. Bruno Montanari began his career in 1999 working in investment banking in London at Deutsche Bank, then Merrill Lynch, before moving into venture capital, initially at CDP Capital, then at Atlas Venture. He joined Omnes Capital in 2010.Bruno currently sits on the board of directors of several companies (including Horama, Novate, Themis) andpreviously served on the boards of various companies such as arGEN-X (Euronext Brussels: ARGX), EOS imaging (Euronext Paris: EOSI), Poxel (Euronext Paris: POXEL). Bruno graduated with a master’s degree in Strategic Management from the HEC business school and holds a PharmD (University Paris V).
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Bruno Montanari invests in
Stages Bruno Montanari invests in
Countries Bruno Montanari invests in
Investment Focus
Industry
- Health Care 4 (80%)
- Biotechnology 4 (80%)
- Medical 3 (60%)
- Medical Device 2 (40%)
- Hospital 1 (20%)
Stage
- Series A 3 (60%)
- Series B 1 (20%)
Country
- Italy 1 (20%)
- France 1 (20%)
- Ireland 1 (20%)
- United Kingdom 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sibylla Biotech
|
Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas. | $23M / Series A / Oct 04, 2022 | |
Storm Therapeutics
|
Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $18.3M / Series A / May 20, 2019 | |
TISSIUM
|
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | Series A / Mar 17, 2016 | |
|
TISSIUM
|
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bindstrongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management. | $8.8M / Series A / Dec 09, 2013 | |
Novate Medical
|
NOvate Medical Technologies is a New Orleans-based medical device development company, focused on commercializing high-quality, low-cost, and sustainable medical products while addressing critical global health needs. NOvate’s first product offering, InfaClip, previously known as SafeSnip, is a patented disposable plastic obstetric device thatsimultaneously cuts, clamps, and shields the infant, mother, and birthing attendant from infection, aimed at reducing maternal and neonatal mortality in developing countries. | $9.9M / Series B / May 21, 2011 |
Co-Investors
About Seroba Life Sciences
Seroba is a life sciences venture capital firm, focused on investing in breakthrough healthcare technologies that promise to improve lives and make a difference worldwide.Headquartered in Ireland, the firm works with some of the world’s best entrepreneurs developing innovative medical devices, diagnostics, and therapeutic drugs. It funds newhealthcare opportunities through key value-adding stages, assisting its invested companies from inception through development and clinical evaluation, the generation of intellectual property, regulatory approvals and market launch, and partnering with leading pharmaceutical or medtech companies.The Seroba team combines in-depth scientific and medical knowledge with broad regulatory and commercial expertise. They are known for patience, understanding, commitment and passion, well-demonstrated by the caliber of entrepreneurs they back, and an overriding focus on delivering improvements to people's lives and value to their stakeholders.
Seroba Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan O'Connell
Partner
|
|||
|
Bruno Montanari
Partner
|
|||
Daniel O' Mahony
Partner
|
|||
Seamus O’Hara
Director
|
|||
Andrew Duignan
CFO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bruno Montanari invest in?
Bruno Montanari invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bruno Montanari last invest?
The most recent investment recorded for Bruno Montanari closed in Oct 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
